ArticleBlood cancer journal2015

Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.

T W Farren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.